2019 New Treatment Guidelines for Peyronie’s Disease

2019 New Treatment Guidelines for Peyronie's Disease


NEW YORK, Nov. 29, 2018 /PRNewswire/ — Andromedical Laboratory has patented and researched Penile Traction Devices for 20 years to develop ANDROPEYRONIE ®, a medical device to treat Peyronie’s disease. Based on a clinical study published in The Journal of Sexual Medicine (Nov-2013, Dr. Martínez-Salamanca et al.), ANDROPEYRONIE ® reduces the penile curvature in more than 50 percent, with a pain reduction, an increasing in penile length of 1.5 cm and an improvement in the sexual function. ANDROPEYRONIE ® is the only device registered by the U.S. Food and Drug Administration for PD. More information in: https://www.andropeyronie.com

The new guidelines, presented by the Canadian Urological Association (CUA) in 2018, recommend the use of remodeling technique based on Penile Traction Device of Andromedical (ANDROPEYRONIE®) in combination with collagenase injections to treat patients with Peyronie’s disease (PD).

Canadian Urological Association recommends penile remodeling with mechanical therapy or penile traction: The use of a traction device to reduce plaque/wound contracture, enhance plaque elasticity, and reduce plaque size is appealing, given its low cost and general freedom from adverse effects. Traction impact on PD cells in a mechanical strained environment results in alteration of connective tissue, demonstrating measurable changes in collagen and tissue metalloproteinase expression, which are two key factors in determining plaque integrity. It appears to have some activity in correcting penile pain, curvature, and maintenance of penile length, with recent reports highlighting a potential synergy with intralesional or oral agents. The current treatment paradigm for PD relies on tissue remodeling for optimal outcomes following both minimally invasive treatment approaches and post-surgical results. More information.

Also, American Urological Association (AUA) in 2015 recommended to medical professionals administer intralesional collagenase clostridium histolyticum in combination with modeling (penile traction therapy) by the physician and by the patient for the decrease of penile curvature in people with stable PD, with a penile curvature > 30 degrees and also < 90 degrees, and intact erectile function. More information.

Dr. Eduardo Gomez, inventor of the Penile Traction Device (PTT), explains, “I recommend a minimum of 8 hours/daily of use for the PTT devices. With less hours, no result is obtained. The future of PD treatment is the combination of penile traction with collagenase injections to obtain the best outcomes, as recommended by urological associations.” More information about Penile Traction Devices.

About Andromedical
Andromedical is a urology Laboratory with ISO 13485 Medical Device Certified which focuses on men’s health devices. Our mission is an improvement in the male sexual function and a correction of penile morphology. We hold health certifications as USA FDA Registration, Canada CMDCAS, CE Declaration of Conformity and Australia ARTG. More company information.

Media Contact:
Dr. Eduardo Gomez de Diego
Phone: 646-568-7796
Email: [email protected]

Related Files


Related Images

Andropeyronie device
Andropeyronie device for Peyronie’s disease

Andropeyronie device box
Andropeyronie device and complements

Andropeyronie is urologist recommended
Andropeyronie recommended

Andropeyronie can cure Peyronie’s disease
Andropeyronie can cure Peyronie’s disease

Related Links



Related Video


SOURCE Andromedical

Related Links



Source link Google News